FDA proposes adding patient voice in device evaluation
FDA proposes adding patient voice in device evaluation

FDA said it considers how patients feel, function and survive to be valid scientific evidence of safety and effectiveness that can be considered in the evaluation and surveillance of medical devices. The data should be considered voluntary and complementary to other outcomes evidence, but may be recommended in some standards and guidance, the agency said.

In clinical studies, a patient-reported outcome instrument could be used to measure the effects of a medical treatment or changes in a patient’s health. The information also could help determine whether a patient is eligible to be included in a study, and to measure primary or secondary safety and effectiveness endpoints, the guidance document suggests.

FDA encouraged manufacturers to seek feedback from the agency during the study design stage, before an investigational device exemption (IDE) is submitted or a pivotal trial is conducted, to determine the relevance and suitability of a proposed patient-reported outcome instrument to the benefit-risk assessment.

Further, outcomes important to patients should be measured and included in medical device submissions, FDA said. In addition to providing evidence of safety and effectiveness, the data could measure a device’s effect on patient well-being and other concepts that may influence healthcare providers’ decisions about possible treatments. Reliable patient data also could prove valuable in medical device labeling to communicate the effect of a treatment on patient symptoms, functioning or quality of life, FDA said.

The new guidance document comes nearly two years after the agency convened its Patient Engagement Advisory Committee to explore ways to incorporate the patient experience and priorities in device design, development and assessment. After the panel meeting, AdvaMed submitted comments to the agency that sought clarification on whether patient input would be sought from broader sources such as advocacy groups.

FDA said it encourages device makers to collaborate with patient organizations, medical groups and research institutions with expertise in patient-reported outcome instruments development. Read more

Also Read: Clinical trial links hospital use of Dexcom G6 to improved glucose control